Generated by AI
Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries. The company develops mission-critical solutions that help manufacturers detect microbial contamination and support the efficient manufacturing and safe release of healthcare products. Its current offerings include the Growth Direct platform, which combines an automated system, proprietary consumables, software for laboratory information management system connectivity, and validation and support services. These products are used across regulated environments involved in biologics, vaccines, cell and gene therapies, sterile injectables, medical devices, and personal care products. Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems serves customers in the United States and international markets, where faster and more reliable microbial testing plays an important role in modern production workflows.
Website25 Hartwell Avenue
Lexington, MA, 02421
United States
The latest articles about RPID.
Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Summary of Mar 12's posts. Generated by AI.
No summary yet.
Summary of Feb 28's posts. Generated by AI.
No summary yet.
Summary of Jan 14's posts. Generated by AI.
Investors talking about RPID also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.